指南与共识临床微生物质量管理与危急值

EUCAST与CLSI药敏结果报告建议的差异:观点交锋

Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results.
指南 / 共识 · J Clin Microbiol · 2019-08-26

本文为观点交锋类文章,讨论欧洲抗菌药物敏感性试验委员会(EUCAST)与美国临床和实验室标准协会(CLSI)在抗菌药物敏感性试验结果报告策略上的差异。文章聚焦于三个复杂情境:是否需要高于常规剂量给药、抗菌药物在感染部位是否可能有效、以及因技术变异导致结果不确定时如何报告。Gunnar Kahlmeter与Christian Giske阐述EUCAST的应对策略,Thomas Kirn与Susan Sharp阐述CLSI的做法。

要点

  • EUCAST与CLSI对药敏结果报告中的复杂情境采取不同策略。
  • 复杂情境包括高剂量给药需求、感染部位药物浓度及技术变异不确定性。
  • 文章由两组织代表分别阐述各自立场与处理方法。

核心结论

  • EUCAST与CLSI在药敏结果报告策略上存在差异,尤其涉及剂量、感染部位浓度及技术变异不确定性等复杂情境。

研究设计与样本

  • 观点交锋类文章,由EUCAST代表Gunnar Kahlmeter和Christian Giske、CLSI代表Thomas Kirn和Susan Sharp分别阐述各自策略。

主要发现

  • EUCAST与CLSI针对药敏试验结果报告中的三类复杂情境采取了不同的应对策略。

临床怎么用

  • 临床微生物实验室应了解EUCAST与CLSI在药敏报告策略上的差异,以便在报告复杂药敏结果时做出合理选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTIONAntibiotic susceptibility test results are among the most important results issued by clinical microbiology laboratories because they routinely guide critical treatment decisions. Interpretations of MIC or disk diffusion test results, such as "susceptible" or "resistant," are easily understood. Clinical laboratories also need to determine whether and how their reports will reflect more complex situations. Such situations include, first, whether there is need to administer higher or more frequent doses of antibiotic than usual for clinical efficacy; second, whether an antimicrobial is likely to be effective at a body site where it concentrates; and third, whether there is some uncertainty in the test results due to technical variability that cannot be eliminated. Two leading organizations that set standards for antimicrobial susceptibility testing, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI), have taken different strategies to deal with these challenges. In this Point-Counterpoint, Gunnar Kahlmeter and Christian Giske discuss how EUCAST is addressing these issues, and Thomas Kirn and Susan Sharp discuss the CLSI approach.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Kahlmeter G, Giske CG, Kirn TJ, et al. Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results. J Clin Microbiol. 2019. PMID: 31315957. doi:10.1128/JCM.01129-19

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。